Foghorn Therapeutics Inc.
NASDAQ:FHTX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.82
9.99
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FHTX stock under the Base Case scenario is 7.023 USD. Compared to the current market price of 8.955 USD, Foghorn Therapeutics Inc. is Overvalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Foghorn Therapeutics Inc.
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FHTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Foghorn Therapeutics Inc.
Balance Sheet Decomposition
Foghorn Therapeutics Inc.
Current Assets | 271.2m |
Cash & Short-Term Investments | 267.4m |
Other Current Assets | 3.8m |
Non-Current Assets | 37.1m |
PP&E | 34.6m |
Other Non-Current Assets | 2.6m |
Current Liabilities | 56.8m |
Accounts Payable | 3.5m |
Accrued Liabilities | 19.8m |
Other Current Liabilities | 33.6m |
Non-Current Liabilities | 279.8m |
Other Non-Current Liabilities | 279.8m |
Earnings Waterfall
Foghorn Therapeutics Inc.
Revenue
|
25.5m
USD
|
Operating Expenses
|
-127.3m
USD
|
Operating Income
|
-101.7m
USD
|
Other Expenses
|
10.5m
USD
|
Net Income
|
-91.2m
USD
|
Free Cash Flow Analysis
Foghorn Therapeutics Inc.
USD | |
Free Cash Flow | USD |
FHTX Profitability Score
Profitability Due Diligence
Foghorn Therapeutics Inc.'s profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Foghorn Therapeutics Inc.'s profitability score is 44/100. The higher the profitability score, the more profitable the company is.
FHTX Solvency Score
Solvency Due Diligence
Foghorn Therapeutics Inc.'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Foghorn Therapeutics Inc.'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FHTX Price Targets Summary
Foghorn Therapeutics Inc.
According to Wall Street analysts, the average 1-year price target for FHTX is 16.32 USD with a low forecast of 9.09 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for FHTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
FHTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.
Contact
IPO
Employees
Officers
The intrinsic value of one FHTX stock under the Base Case scenario is 7.023 USD.
Compared to the current market price of 8.955 USD, Foghorn Therapeutics Inc. is Overvalued by 22%.